20 results
DEF 14A
NAMS
NewAmsterdam Pharma Company NV
9 May 24
Definitive proxy
4:15pm
of Directors
Nasdaq Board Diversity Matrix
Director Attendance at Board and Shareholder Meetings
Board of Directors Committees
Director Nomination Process
Risk … ownership of our capital stock by each director.
Nasdaq Board Diversity Matrix
Board Diversity Matrix (As of April 15, 2024)
Country of Principal
PRE 14A
NAMS
NewAmsterdam Pharma Company NV
29 Apr 24
Preliminary proxy
5:00pm
Nasdaq Board Diversity Matrix
Director Attendance at Board and Shareholder Meetings
Board of Directors Committees
Director Nomination Process
Risk … .
Nasdaq Board Diversity Matrix
Board Diversity Matrix (As of April 15, 2024)
Country of Principal Executive Offices
Netherlands
Foreign Private Issuer
POS AM
NAMS
NewAmsterdam Pharma Company NV
12 Apr 24
Prospectus update (post-effective amendment)
4:15pm
adopted a diversity policy for the composition of the Board of Directors, as well as a profile for the composition of the Board of Directors … regard to the rules and principles set forth in such diversity policy and profile, as applicable. Our directors serve staggered terms as set out
424B3
NAMS
NewAmsterdam Pharma Company NV
12 Mar 24
Prospectus supplement
4:18pm
will make a new nomination.
We have adopted a diversity policy for the composition of the Board of Directors, as well as a profile for the composition … for the appointment of a director with due regard to the rules and principles set forth in such diversity policy and profile, as applicable. Our
POS AM
NAMS
NewAmsterdam Pharma Company NV
28 Feb 24
Prospectus update (post-effective amendment)
5:01pm
nomination, the Board of Directors will make a new nomination.
We have adopted a diversity policy for the composition of the Board of Directors, as well … of Directors will make any nomination for the appointment of a director with due regard to the rules and principles set forth in such diversity policy
10-K
63n8svse2cbp6j
28 Feb 24
Annual report
8:00am
10-K
EX-4.4
3j33wp3i01
28 Feb 24
Annual report
8:00am
424B5
mttgpt4 zl8g
15 Feb 24
Prospectus supplement for primary offering
4:15pm
424B5
wgk1ww0rcf26o8 4gga5
13 Feb 24
Prospectus supplement for primary offering
5:19pm
F-3
iv9e9d
7 Dec 23
Shelf registration (foreign)
4:16pm
424B3
8pxnrvlx79osi9zk1e
15 Aug 23
Prospectus supplement
4:52pm
POS AM
cje52c50uxot7 b4apu
7 Aug 23
Prospectus update (post-effective amendment)
7:56am
424B3
l7ya 8sh6nnwavp
8 Jun 23
Prospectus supplement
5:01pm
424B3
srme2
6 Jun 23
Prospectus supplement
4:20pm
6-K
EX-99.1
gpr18lncp mn8
31 May 23
Current report (foreign)
8:00am
424B3
mz3wd5v3
25 Apr 23
Prospectus supplement
8:14am
POS AM
0xdl3lvsy515p1yt
17 Apr 23
Prospectus update (post-effective amendment)
9:09am
F-1
p58ri0oiy
19 Dec 22
Registration statement (foreign)
6:22pm
- Prev
- 1
- Next